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Despite exponential growth in the
past decades, most aspects of the as-
sisted reproductive technology (ART)
industry remain largely unregulated;
recently, pressure has been mount-
ing for coordinated study and regula-
tion of this developing industry.' On
March 28, 2008, lawyers, health care
professionals, representatives from
sperm banks, consumers of ART ser-
vices, and other stakeholders in ART
industry gathered at DePaul Univer-
sity College of Law for its Health Law
Institute's symposium titled "Track-
ing Change: The Feasibility of a Vol-
untary Gamete Donor Registry in the
United States." The implementation
of a registry would mark the first ef-
fort in the United States to centralize,
maintain, and disseminate informa-
tion about gamete donors by collect-
ing and storing genetic and iden-
tifying information about egg and
sperm donors.2 Establishing a reg-
istry requires balancing the interests
of donor-conceived individuals, their
parents, gamete donors, health care
professionals, and society as a whole,
as well as ensuring the privacy and
safety of all involved. Further, the
consideration of a voluntary registry
invites debate about the desirability
of a mandatory registry and increased
systematic consideration and regula-
tion of ART generally.
Background
Currently, it is impossible to know the
exact number of donor-conceived in-
dividuals in the United States because
no federal, state, or private agency
tracks donor-conceived births.4 The
ART industry in the United States
is regulated primarily by voluntary
guidelines issued by organizations
such as the American Society for
Reproductive Medicine (ASRM); as
these guidelines are advisory only,
the extent to which they are followed
is unclear.5 There are few federal or
state regulations, and those that do
exist are not comprehensive.6 Thus,
the result is a decentralized, private
industry that has yielded a norm of
anonymous gamete donation, an ab-
sence of information about the intri-
cacies of the market for gametes and
the effects of ART, confusion about
the legal consequences of gamete do-
nation, inconsistent record keeping
of births, and a dearth of resources
for donor-conceived individuals in
search oftheir biological progenitors.7
Nowhere is this result more evident
than in the realm of gamete dona-
tion: there are 26 sperm banks (five
of which supply 75-80% of sperm
distributed) and several hundred egg
donor programs in the United States,
most operating according to their
own standards. An accurate estimate
of the number of egg donor programs
is impossible as no registration, li-
censing, or other requirements exist
to track such entities."
In contrast to the United States'
model, many other countries heavily
regulate ART, including mandating
the non-anonymity of donors.9 His-
torically, the United States' norm of
donor anonymity and overall lack of
regulation of ART reflected infertil-
ity's stigma, a national emphasis on
personal autonomy and privacy, and
a heated political debate over abor-
tion.10 Nevertheless, in recent years,
the desirability of anonymous gamete
donation has come into question, es-
pecially with regard to the interests
of donor-conceived individuals (and
their parents) in learning about their
genetic origins." Donors themselves
also have advocated for open-identity
donation, indicating an interest in
knowing the outcome of their dona-
tion and a willingness to have con-
tact with offspring. 2 This change in
the perspective of ART participants
has resulted in the following: (1)
prompted the ASRM to promulgate
guidelines advocating the collection
and distribution of donors' genetic
information upon request to donor-
conceived individuals and their par-
ents; 13 (2) led to the creation of Web
sites dedicated to linking donor-con-
ceived children with their genetic
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half-siblings and donor "parents"
if all parties are in agreement; 14 (3)
encouraged sperm banks to establish
open-identity donor programs that
operate alongside anonymous dona-
tion programs; 15 and (4) fostered an
increase in the ratio of open-identity
to anonymous donors.'6
Overall, there has been a trend to-
ward open-identity donation, a term
that describes gamete donors who
agree to release their identifying in-
formation to their offspring when
those offspring reach adulthood. As
noted at the symposium, there also
has been a recognition that all partici-
pants in the gamete donation process
may have an interest in the collection,
of information that a registry would
facilitate and provided a forum for
the key stakeholders to discuss the
benefits, drawbacks, and design of a
voluntary registry.
The symposium's participants pri-
marily examined how a registry might
be designed to ensure that donor-
conceived individuals' (or their par-
ents') desire to access their biological
progenitors might be advanced while
protecting the interests of donors
and parents. Even enabling this uni-
directional exchange of information
between donor-conceived individuals
and their biological progenitors has
the potential to generate benefits for
many more stakeholders. Assuming
Moreover, the societal benefits
that may accrue from such a registry
are immense. For example, track-
ing gamete donation could address
a concern about inadvertent consan-
guinity.2 0 Beyond identifying geneti-
cally related individuals by follow-
ing who is donating gametes where
and when and the outcome of ART
cycles using those gametes, health
care professionals and researchers
could draw upon information con-
tained in a registry to generate data
to better study the effects of ART on
consumers of ART services, donors,
and offspring. An improved under-
standing of ART may provide empiri-
cal grounds for the establishment of
An improved understanding of ART may provide empirical grounds for
the establishment of national standards for gamete donors and individuals
undergoing ART procedures, limits on the number of children created
by one individual's gametes, limits on how many times or how frequently
one individual may donate gametes, and regulation of the solicitation and
compensation of gamete donors. Further, a registry may increase society's
confidence in and acceptance of gamete donation, while simultaneously
recognizing its uniqueness as a means to facilitate procreation.
maintenance, and disclosure of infor-
mation about gamete donors. The
confluence of these developments is
why "Tracking Change" assembled
key stakeholders in the ART industry
to debate the creation of a national
voluntary gamete registry.
Benefits, Drawbacks, and
Feasibility of a Registry
One of the main impetuses to creat-
ing a national voluntary gamete reg-
istry is donor-conceived individuals'
(or their parents') desire to access in-
formation about their genetic origins.
However, a registry would not merely
be a place for donor-conceived indi-
viduals to go in search of their genetic
origins, but it would also be a central
database of information for health
care professionals, researchers, con-
sumers of ART services, donors, and
half-siblings. "Tracking Change" fo-
cused on the multi-directional flow
donor-conceived individuals know
they are donor conceived, accessing
such information may advance their
psychological well-being and sense of
self. Similarly, if desired by all par-
ties involved, the information could
facilitate the connection and possible
meeting of donors and genetic half-
siblings, likewise improving the psy-
chological well-being of donors and
genetic half-siblings. A registry also
could provide updated medical infor-
mation about a donor's offspring and
genetic half-siblings, which would
provide an added medical - in ad-
dition to psychological - benefit for
these parties. 8 Though medical in-
formation is routinely collected from
donors at the time of donation, this
information is rarely updated; medi-
cal history is almost never collected
from donor-conceived individuals
for use by their donors and genetic
half-siblings. 9
national standards for gamete donors
and individuals undergoing ART
procedures, limits on the number of
children created by one individual's
gametes, limits on how many times
or how frequently one individual may
donate gametes, and regulation of
the solicitation and compensation of
gamete donors. Further, a registry
may increase society's confidence in
and acceptance of gamete donation,
while simultaneously recognizing its
uniqueness as a means to facilitate
procreation, thus responding to ethi-
cal arguments about the commodifi-
cation that may accompany gamete
donation and ART. This may in turn
result in reduction of the stigma as-
sociated with infertility.2'
Realizing these personal and soci-
etal benefits requires negotiating the
potentially adverse interests of donors
and the parents of donor-conceived
individuals. Legally, donors may have
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a right to prevent disclosure of their
identifying information, and disclo-
sure may violate the recipient parents'
privacy. Conflictingly, donor-con-
ceived individuals may have a right to
know information about themselves
under certain circumstances. Though
a gamete registry could be designed
to address donors' privacy concerns
by allowing the disclosure of donors'
identifying information only upon
their approval or precluding contact
without their consent, donors' signifi-
cant concerns about their parentage
status remain. A majority of states do
have laws relieving sperm donors of
parental rights so long as the intended
parent(s) have consented, but only a
few states have enacted similar leg-
islation addressing egg and embryo
donation. Further, even if donors are
willing to submit their information to
a registry, the lack of well-established
and tested regulations may dissuade
participation. 22
Disincentives from uncertain legal
regimes is but one of a number of
barriers to implementation of a reg-
istry. The tension between intended
parents' privacy and the ability of
donor-conceived individuals to ac-
cess their genetic origins raises the
question of how children might learn
that they are donor-conceived in the
first place, which was largely beyond
the symposium's scope. Additionally,
though a registry may provide health
care professionals with greater infor-
mation about how ART affects their
patients, thereby allowing them to
better inform and follow-up with pa-
tients, health care professionals note
that a registry may intrude upon the
practice of medicine. For example, it
may increase the already high cost of
ART, pricing more people out of these
services; it may decrease the availabil-
ity of gametes by reducing donations;
and it may encourage international
reproductive travel. 23
Logistical implementation issues
also must be resolved. Open ques-
tions include who will be responsible
for gathering information and ensur-
ing its protection, how data will be
verified, and what should be done
with outdated records. 24 Though no
concrete proposal for a voluntary reg-
istry was discussed at the symposium,
the three largest sperm banks in the
United States have advocated for the
creation of a voluntary registry run
by a non-profit entity governed by a
board of directors elected by its mem-
bers, who will fund the non-profit and
be comprised of sperm banks and egg
donation programs.25  Yet, funding
sources are influential, which leads
others to question the appropriate-
ness of vesting regulation in the in-
dustry being regulated.2
6
Overall, symposium participants
agreed that even if the implementa-
tion issues associated with a purely
voluntary registry prevent the full re-
alization of the potential societal and
personal benefits discussed, the cre-
ation of a voluntary national gamete
registry is a step in the right direction
when compared with the status quo
of sparsely regulated and sporadic re-
cord keeping.
What Should Voluntary Mean,
and Is a Mandatory Registry
Desirable?
Questions about implementation
led some participants to assert that
a mandatory registry is necessary, al-
though the symposium's participants
only briefly discussed the relative
merits of a mandatory versus a vol-
untary registry. Some time was spent
considering the related question of
what "voluntary" should mean. The
medical or psychological benefits that
donor-conceived individuals might
experience could be undermined
if parties opt-out at any one of sev-
eral moments in a purely voluntary
scheme. Some sperm banks and egg
donor programs may decline to par-
ticipate in the registry, and donors
within a participating program may
themselves decline to provide infor-
mation or may choose to provide only
partial information. For example, a
donor-conceived individual would
only be able to access her genetic in-
formation or connect with her bio-
logical relative(s) if her parents chose
a fully participating donor from a
participating program. Further, the
larger societal benefits noted above
have little chance of being realized
without a guarantee that a threshold
level of information will be collected
and maintained.
A mandatory registry would ensure
that donor-conceived individuals
are able to access information about
their biological origins while pro-
tecting the privacy of donors by in-
cluding safeguards concerning when
and how donors may be contacted.
Moreover, a mandatory registry may
prompt federal and state legislators
to enact statutes to resolve legal is-
sues surrounding ART. Finally, a
mandatory registry would guarantee
that health care professionals and
researchers have robust information
to consult when studying ART tech-
niques. 27 However, given the United
States' strong emphasis on personal
autonomy and privacy, even if a man-
datory registry is desirable, it may not
be politically realistic.
Potential Impact on the Assisted
Reproductive Technology Industry
As the first real national response
to any consumer aspect of the ART
industry, the mere proposal of a
national registry has the potential
to impact the ART industry far
beyond providing for the needs of
the donor-conceived individuals who
initially motivated its suggestion,
thus highlighting other aspects of the
ART industry that invite systematic
consideration and regulation.
Although a discussion of these other
aspects was almost entirely beyond
the scope of "Tracking Change," it
is interesting to hypothesize about
some possible impacts of a registry
on the ART industry that were only
referenced in passing or not raised at
the symposium.
In discussing the ART industry,
commentators have focused on the
consumers of ART services,2 ART's
corollaries with and effects on adop-
tion,29 and class inequalities in access
to ART30 as aspects of the industry
that could benefit from increased
regulation. Additionally, the need for
counseling of all participants in the
ART process was specifically men-
tioned at the symposium. But per-
haps the most important consequence
of increased discussion of ART is the
potential to improve recognition of
how most aspects of ART, especially
egg donation, affect women. Egg do-
nation is complicated, painful, and
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potentially life-threatening21 With
several hundred egg donor programs
in the United States, it is virtually im-
possible to ensure that every woman
who donates eggs is fully informed
about the dangers of the procedure
and that egg donation programs are
taking the necessary safety precau-
tions. Moreover, women themselves
have become commercialized and
sexualized apart from the eggs they
donate, vastly more so than sperm
donors. 32 Not only do select col-
lege students' eggs fetch upwards
of $100,000,33 an existing Web site
offers the opportunity to bid on the
eggs of the female models whose
pornographic pictures members pay
a monthly fee to view.34 Such high
monetary values placed on certain
women's eggs engenders questions
about the frequency with which some
women donate eggs, which may bring
both physical and mental health risks
of its own 5
Further, little research has been
conducted regarding the effects of
multiple cycles of ART, multifetal
pregnancies, and multifetal preg-
nancy reduction on a woman's body
and psyche.36 While a registry may
provide a forum for data collection
that will aid research into the effects
of ART techniques, it has a much
greater potential to highlight egg
donation practices as purchasers of
eggs consider obtaining eggs from a
donor that participates in the regis-
try, especially now that eggs can be
frozen and the egg market increas-
ingly resembles the impersonal
sperm market.37 Though there is a
possibility that the conditions of egg
procurement could become more ob-
scured and worrisome, this transition
to an impersonal market more likely
will cause egg donor programs that
participate in the national registry to
be the primary places egg purchasers
obtain open-identity donated eggs, a
result that will encourage more uni-
form scrutiny and verification of the
how those eggs were obtained.
Any sustained direct focus on how
ART affects its many stakeholders has
the potential to be extremely valuable.
"Tracking Change" centered on the
benefits of a national voluntary gam-
ete registry to donor-conceived indi-
viduals in search of their biological
origins and to other stakeholders who
may access the information in the
registry. Entwined in the discussion
of how best to implement a registry to
achieve those benefits is a broader de-
bate about the regulation of the ART
industry. The creation of a voluntary
registry has the potential to advance
the interests of donor-conceived indi-
viduals, their parents, gamete donors,
and health care professionals, and in
doing so, to highlight other aspects of
the ART industry that are in need of
systematic consideration at a time of
rapid technological innovation.
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